Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T13:30:20.559Z.
Calculation as of: 2026-10-06T13:30:20.559Z.
Quote observation: 2026-10-06T13:30:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f621ea2a381ac0066d385c57ed104ff22630177ee14cd635e65ed0429d7856c2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Aclaris Therapeutics, Inc.
Market Cap
$589.38M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$595.38M
Operating Cash Flow Yield
1.24%
TTM Avg
1.34%
3Y Avg
1.34%
5Y Avg
1.34%
Market Cap
$583.37M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$579.66M
Operating Cash Flow Yield
N/A
TTM Avg
8.85%
3Y Avg
8.85%
5Y Avg
8.85%
Market Cap
$578.97M
Operating Cash Flow Yield
43.86%
TTM Avg
19.98%
3Y Avg
17.70%
5Y Avg
17.70%
Market Cap
$598.37M
Operating Cash Flow Yield
31.01%
TTM Avg
16.53%
3Y Avg
24.40%
5Y Avg
19.97%
Market Cap
$568.20M
Operating Cash Flow Yield
N/A
TTM Avg
4.06%
3Y Avg
4.43%
5Y Avg
13.92%
Market Cap
$554.90M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$549.24M
Operating Cash Flow Yield
3.57%
TTM Avg
3.98%
3Y Avg
3.57%
5Y Avg
3.57%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $589.38M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $595.38M | 1.24% | 1.34% | 1.34% | 1.34% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $583.37M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $579.66M | N/A | 8.85% | 8.85% | 8.85% |
| CorMedix Inc. (CRMD)vs › | $578.97M | 43.86% | 19.98% | 17.70% | 17.70% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 31.01% | 16.53% | 24.40% | 19.97% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $568.20M | N/A | 4.06% | 4.43% | 13.92% |
| Immix Biopharma, Inc. (IMMX)vs › | $554.90M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $549.24M | 3.57% | 3.98% | 3.57% | 3.57% |
| Crescent Biopharma, Inc. (CBIO)vs › | $548.99M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
